{"id":787758,"date":"2026-01-30T13:20:02","date_gmt":"2026-01-30T13:20:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=787758"},"modified":"2026-01-30T13:20:02","modified_gmt":"2026-01-30T13:20:02","slug":"global-rsv-vaccines-market-set-to-reach-us124-billion-by-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-rsv-vaccines-market-set-to-reach-us124-billion-by-2030_787758.html","title":{"rendered":"Global RSV Vaccines Market Set to Reach US$1.24 Billion by 2030"},"content":{"rendered":"
\"Global<\/a><\/div>\n
Respiratory Syncytial Virus (RSV) Vaccines Market by Technology (Recombinant, Inactivated & Subunit, Others), Type (Monovalent, Multivalent), End User (Pediatric, Adult) & Region \u2013 Global Forecast to 2030<\/div>\n

The global Respiratory Syncytial Virus (RSV) vaccines market<\/strong> is transitioning into a new phase of maturity as early launch momentum gives way to normalization in demand, evolving immunization strategies, and increased competitive intensity. Valued at $1.53 billion in 2024<\/strong> and $1.60 billion in 2025<\/strong>, the market is projected to decline at a CAGR of 4.9% from 2025 to 2030<\/strong>, reaching a forecasted valuation of $1.24 billion by 2030<\/strong>.<\/p>\n

This trajectory reflects not a loss of clinical relevance, but a recalibration following rapid initial uptake. What is driving the market today?<\/strong> A sustained global RSV disease burden among infants, older adults, and high-risk populations<\/strong>, combined with expanding adult and maternal immunization policies<\/strong>, continues to support baseline demand. At the same time, seasonality, pricing pressures, and competition from alternative prevention strategies are reshaping commercial expectations.<\/p>\n

Download PDF Brochure:- https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=91874426<\/a><\/strong><\/p>\n

RSV Vaccination Moves from Breakthrough to Routine Prevention<\/strong><\/p>\n

The RSV vaccines market continues to benefit from recent regulatory approvals and commercial launches<\/strong>, which have strengthened physician confidence and improved patient awareness. Who is adopting these vaccines?<\/strong> Health systems are increasingly prioritizing protection for older adults and maternal immunization to reduce RSV-related infant hospitalizations. This shift is positioning RSV vaccination as a routine component of preventive care rather than an episodic intervention.<\/p>\n

Pharmaceutical companies remain active in next-generation RSV vaccine development<\/strong>, including updated formulations and potential combination vaccines<\/strong> targeting multiple respiratory pathogens. These innovations aim to extend product lifecycles and enhance differentiation as competition intensifies.<\/p>\n

Public Health Infrastructure and Platform Innovation Support Market Stability<\/strong><\/p>\n

The market is supported by expanding healthcare infrastructure, active oversight by agencies such as the CDC and FDA<\/strong>, and rising public health awareness of RSV prevention. How are companies responding?<\/strong> Increased R&D investment by leading pharmaceutical players is accelerating innovation in RSV fusion protein–based platforms, which offer improved consistency in efficacy and safety.<\/p>\n

These sophisticated vaccine platforms are particularly important for adult and high-risk infant populations<\/strong>, reinforcing RSV immunization as a strategic priority within broader respiratory disease management frameworks.<\/p>\n

Trends and Disruptions Reshaping Downstream Demand<\/strong><\/p>\n

Following late-stage clinical readouts and approvals, RSV vaccination is shifting decisively from pipeline development to real-world implementation<\/strong>. Health systems are focusing on targeted immunization strategies<\/strong>, balancing cost-effectiveness with population-level impact. While adoption is rising in priority groups, near-term market contraction reflects post-launch normalization and increased scrutiny on pricing, safety, and comparative value.<\/p>\n

Key Market Dynamics<\/strong><\/p>\n